Landscape Capital Management L.L.C. Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Landscape Capital Management L.L.C. grew its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 240.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 10,484 shares of the pharmaceutical company’s stock after buying an additional 7,405 shares during the period. Landscape Capital Management L.L.C.’s holdings in Vertex Pharmaceuticals were worth $4,106,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Hohimer Wealth Management LLC grew its position in Vertex Pharmaceuticals by 1.2% in the second quarter. Hohimer Wealth Management LLC now owns 2,123 shares of the pharmaceutical company’s stock worth $945,000 after acquiring an additional 26 shares in the last quarter. Legacy Wealth Asset Management LLC raised its position in Vertex Pharmaceuticals by 1.8% during the third quarter. Legacy Wealth Asset Management LLC now owns 1,442 shares of the pharmaceutical company’s stock valued at $565,000 after purchasing an additional 26 shares in the last quarter. Quent Capital LLC lifted its stake in Vertex Pharmaceuticals by 5.5% during the third quarter. Quent Capital LLC now owns 501 shares of the pharmaceutical company’s stock worth $196,000 after purchasing an additional 26 shares during the last quarter. Washington Trust Advisors Inc. lifted its stake in Vertex Pharmaceuticals by 8.0% during the third quarter. Washington Trust Advisors Inc. now owns 349 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 26 shares during the last quarter. Finally, Defined Wealth Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 3.0% in the 3rd quarter. Defined Wealth Management LLC now owns 932 shares of the pharmaceutical company’s stock worth $365,000 after purchasing an additional 27 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

VRTX traded down $2.49 during midday trading on Friday, reaching $475.64. 83,806 shares of the company’s stock traded hands, compared to its average volume of 1,496,498. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The firm has a fifty day moving average of $469.68 and a two-hundred day moving average of $437.20. The stock has a market capitalization of $120.83 billion, a price-to-earnings ratio of 31.01, a P/E/G ratio of 2.10 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period last year, the firm posted $3.98 earnings per share. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 260 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $126,451.00. Following the transaction, the executive vice president directly owned 46,763 shares of the company’s stock, valued at approximately $22,743,185.05. The trade was a 0.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the sale, the executive vice president directly owned 17,559 shares in the company, valued at $8,562,646.35. The trade was a 21.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 91,156 shares of company stock valued at $42,845,497 over the last quarter. 0.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on VRTX shares. Stifel Nicolaus increased their price objective on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Scotiabank increased their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Royal Bank Of Canada lowered their price objective on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating for the company in a report on Friday, February 13th. HC Wainwright increased their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 4th. Twenty-three equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $553.36.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Multiple firms raised coverage/targets and reiterated buys, adding upward pressure on sentiment — Oppenheimer to $600, Truist to $525, plus bullish notes from Morgan Stanley, Citi and BofA. Oppenheimer Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $600.00 Truist Raises Price Target Morgan Stanley Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
• Positive Sentiment: Analyst activity lifted intraday momentum (shares were reported trading ~9.9% higher on an upgrade earlier this week), reinforcing bullish flows into VRTX. Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher on Analyst Upgrade
• Positive Sentiment: Jefferies initiated research coverage this week, which can increase institutional attention and liquidity. Vertex Pharmaceuticals (NASDAQ:VRTX) Research Coverage Started at Jefferies Financial Group
• Neutral Sentiment: Market commentary and roundup pieces note VRTX is trending among retail readers and across Nasdaq index focus lists — helpful for visibility but not directly catalytic. Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock
• Neutral Sentiment: Company presentation transcript from Barclays’ healthcare conference is available for detail on pipeline/progress — useful for fundamental assessment but not an immediate price driver. Vertex Presents at Barclays Conference Transcript
• Neutral Sentiment: Long‑term performance retrospectives and broader Nasdaq mentions support visibility but are background context rather than catalysts. If You Invested $1000 In Vertex Pharmaceutical Stock 20 Years Ago
• Negative Sentiment: There was a recent pullback (reported March 11) when VRTX fell more than the market (about -1.36% that session), indicating profit‑taking and volatility following the run-up. Vertex Registers a Bigger Fall Than the Market
• Negative Sentiment: Recent quarterly results included a very small EPS miss (Feb 12: $5.03 vs est. $5.05) — fundamentals remain strong but misses and a high P/E leave the stock vulnerable to sentiment swings. Earnings and Trading Note

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.